[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] DAVIS R T, BLAKE K, MA D, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing[J]. Nat Cell Biol, 2020, 22(3):310-320.
[3] SJOSTROM M, CHANG S L, FISHBANE N, et al. Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy[J]. Clin Cancer Res, 2020, 26(1):171-182.
[4] ABU-JAMOUS B, BUFFA F M, HARRIS A L, et al. In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer[J]. Mol Cancer, 2017, 16(1):105.
[5] BOUCHAL P, SCHUBERT O T, FAKTOR J, et al. Breast cancer classification based on proteotypes obtained by SWATH mass spectrometry[J]. Cell Rep, 2019, 28(3):832-843.
[6] MONTI C, ZILOCCHI M, COLUGNAT I, et al. Proteomics turns functional[J]. J Proteomics, 2019, 198:36-44.
[7] KHALKHAL E, REZAEI-TAVIRANI M, ROSTAMII-NEJAD M.Pharmaceutical advances and proteomics researches[J]. Iran J Pharm Res, 2019, 18(Suppl 1):51-67.
[8] ASLAM B, BASIT M, NISAR M A, et al. Proteomics:technologies and their applications[J]. J Chromatogr Sci, 2017, 55(2):182-196.
[9] OPSTAL-VAN W A, VERMEULEN R C, PEETERS P H, et al. Early diagnostic protein biomarkers for breast cancer:how far have we come?[J]. Breast Cancer Res Treat, 2012, 134(1):1-12.
[10] WAKS A G, WINER E P.Breast cancer treatment:a review[J]. JAMA, 2019, 321(3):288-300.
[11] TYANOVA S, ALBRECHTSEN R, KRONQVIST P, et al. Proteomic maps of breast cancer subtypes[J]. Nat Commun, 2016, 7:10259.
[12] MERTINS P, MANI D R, RUGGLES K V, et al. Proteogenomics connects somatic mutations to signalling in breast cancer[J]. Nature, 2016, 534(7605):55-62.
[13] YANOVICH G, AGMON H, HAREL M, et al. Clinical proteomics of breast cancer reveals a novel layer of breast cancer classification[J]. Cancer Res, 2018, 78(20):6001-6010.
[14] POZNIAK Y, BALINT-LAHAT N, RUDOLPH J D, et al. System-wide clinical proteomics of breast cancer reveals global remodeling of tissue homeostasis[J]. Cell Syst, 2016, 2(3):172-184.
[15] KRUG K, JAEHNIG E J, SATPATHY S, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy[J]. Cell, 2020, 183(5):1436-1456.
[16] GAJBHIYE A, DABHI R, TAUNK K, et al. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes[J]. J Proteomics, 2017, 163:1-13.
[17] YIGITBASI T, CALIBASI-KOCAL G, BUYUKUSLU N, et al. An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry[J]. Biomed Rep, 2018, 8(3):269-274.
[18] FREDOLINI C, PATHAK K V, PARIS L, et al. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection[J]. Breast Cancer Res, 2020, 22(1):135.
[19] BERA A, RUSS E, MANOHARAN M S, et al. Proteomic analysis of inflammatory biomarkers associated with breast cancer recurrence[J]. Mil Med, 2020, 185(Suppl 1):669-675.
[20] ZOGRAFOS E, ANAGNOSTOPOULOS A K, PAPADOPOULOU A, et al. Serum proteomic signatures of male breast cancer[J]. Cancer Genomics Proteomics, 2019, 16(2):129-137.
[21] WALASZCZYK A, PIETROWSKA M, WOJAKOWSKA A, et al. Therapy-related changes in the serum proteome patterns of early stage breast cancer patients with different outcomes[J]. Protein Pept Lett, 2017, 24(1):37-45.
[22] YANG T, FU Z, ZHANG Y, et al. Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer[J]. Biomed Pharmacother, 2020, 129:110465.
[23] CHEN E I, CREW K D, TRIVEDI M, et al. Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology[J]. PLoS One, 2015, 10(12):e145816.
[24] DEBALD M, WOLFGARTEN M, WALGENBACH-BRUNAGEL G, et al. Non-invasive proteomics-thinking about personalized breast cancer screening and treatment[J]. EPMA J, 2010, 1(3):413-420.
[25] BRUNORO G V, FERREIRA A T, TRUGILHO M R, et al. Potential correlation between tumor aggressiveness and protein expression patterns of nipple aspirate fluid(NAF) revealed by gel-based proteomic analysis[J]. Curr Top Med Chem, 2014, 14(3):359-368.
[26] BRUNORO G V, CARVALHO P C, BARBOSA V C, et al. Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow[J]. BMC Cancer, 2019, 19(1):365.
[27] SHAHEED S U, TAIT C, KYRIACOU K, et al. Nipple aspirate fluid-A liquid biopsy for diagnosing breast health[J]. Proteomics Clin Appl, 2017, 11(9-10):1700015.
[28] GIRI K, MEHTA A, AMBATIPUDI K.In search of the altering salivary proteome in metastatic breast and ovarian cancers[J]. FASEB Bioadv, 2019, 1(3):191-207.
[29] KIM J, KIM W T, KIM W J.Advances in urinary biomarker discovery in urological research[J]. Investig Clin Urol, 2020, 61(Suppl 1):S8-S22.
[30] WANG Y T, SHI T, SRIVASTAVA S, et al. Proteomic analysis of exosomes for discovery of protein biomarkers for prostate and bladder cancer[J]. Cancers(Basel), 2020, 12(9):2335.
[31] PORIES S E, ZURAKOWSKI D, ROY R, et al. Urinary metalloproteinases:noninvasive biomarkers for breast cancer risk assessment[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(5):1034-1042.
[32] BERETOV J, WASINGER V C, MILLAR E K, et al. Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach[J]. PLoS One, 2015, 10(11):e141876.
[33] GAJBHIYE A, DABHI R, TAUNK K, et al. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics[J]. Proteomics, 2016, 16(17):2403-2418. |
